Causal AI-based clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in early-stage NSCLC: a secondary analysis of the phase II I-SABR trial is a research paper published in Journal for ImmunoTherapy of Cancer (2025). On theSindex it has a DataRank of 0.241. It has been cited 4 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.241
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Cancer Institute at the National Institutes of Health through the Cancer Cen-ter Core
Grant: P30CA016672
Clinical and Translational Science Award
Grant: UL1 RR024148
Bristol-Myers Squibb and MD Anderson Cancer Center Alliance
Grant: CA209-925
Texas 4000 Distinguished Professorship at the MD Anderson Cancer Center and the Joan and Herb Kelleher Charitable Foundation
Grant: N/A
FWCI
3.82
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords